Intensity Therapeutics, Inc.INTS

Intensity Therapeutics Inc. is a clinical-stage oncology outfit chasing an intratumoral therapy called INT230-6, designed to deliver cytotoxic and immunomodulatory agents directly into solid tumours. The company’s story is built on the premise that local delivery can wake up the immune system without the systemic toxicity of traditional chemo. So far, the premise is still in the lab; the income statement is in the red. (source: SEC EDGAR filings index, https://www.sec.gov/edgar/browse/?CIK=1567264)

What changed this week was not a product launch or a trial readout, but a flurry of insider option grants that vest in tidy, annual instalments-four times over-beginning on 16 July 2026. Five separate Form 4s from executives and directors confirm identical vesting schedules, a rare harmony in corporate disclosure that hints at a board keen to align incentives with longevity, not liquidity. The optics read like a loyalty programme for talent, not a growth plan for shareholders. (source: SEC EDGAR Form 4 filings, https://www.sec.gov/Archives/edgar/data/1567264/000193418826000002/xslF345X06/wk-form4_1784577834.xml)

The latest 10-Q for the quarter ended 31 March 2026 shows $12.3 million in total assets, $10.2 million in cash and equivalents, $2.3 million in liabilities, and a shareholders’ equity line of $10.0 million. Net loss attributable to the parent was $2.4 million; operating loss was $2.5 million; and net cash used in operating activities was $1.8 million. Research and development spend was $1.2 million. Diluted loss per share was $-0.96 on 2.5 million diluted shares. There is no revenue line in the P&L, no product on the market, and no cash dividend. (source: SEC EDGAR 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1567264/0001567264-26-000010-index.htm)

The company’s public materials describe INT230-6 as a proprietary, first-in-class, intra-tumoral drug designed to debulk tumours and turn “cold” microenvironments “hot” for immune attack. The clinical pipeline lists phase 2 trials in solid tumours, but the regulatory filings do not disclose any approvals, sales, or partnerships. The only hard facts are the losses and the vesting schedules. (source: SEC EDGAR company facts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001567264.json)

For readers tracking the company through SEC rails, the raw data lives at the EDGAR index, the submissions feed, and the company facts JSON. There is The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. (source: SEC EDGAR index, submissions JSON, company facts JSON, https://www.sec.gov/edgar/browse/?CIK=1567264, https://data.sec.gov/submissions/CIK0001567264.json, https://data.sec.gov/api/xbrl/companyfacts/CIK0001567264.json)

What remains unproven are the revenue story, the clinical efficacy readouts, and the path to profitability. The board’s option vesting cadence suggests a long runway is the real product on display. Until the P&L shows green, the INT story is still a promise printed on glossy paper and underlined in stock-option ink. (source: SEC EDGAR filings, 2026-07-25)